<SEC-DOCUMENT>0001181431-13-063742.txt : 20131219
<SEC-HEADER>0001181431-13-063742.hdr.sgml : 20131219
<ACCEPTANCE-DATETIME>20131219160125
ACCESSION NUMBER:		0001181431-13-063742
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131219
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131219
DATE AS OF CHANGE:		20131219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		131288381

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rrd398069.htm
<TEXT>

<html>
	<head>
		<meta content="text/html; charset=iso-8859-1">
		<title>
			Prepared By R.R. Donnelley Financial -- Form 8-K
		</title>
	</head>
	<body Bgcolor="white">
		<hr Size="4" Noshade Color="#000000" Align="left">
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="4" Color="#000000">
				<b>UNITED STATES </b>
			</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="4" Color="#000000">
				<b>SECURITIES AND EXCHANGE COMMISSION</b>
			</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="2" Color="#000000">
				<b>Washington, D.C. 20549</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="5" Color="#000000">
				<b>Form 8-K </b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="4" Color="#000000">
				<b>CURRENT REPORT</b>
			</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="4" Color="#000000">
				<b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="3" Color="#000000">
				<b>Date of Report (Date of earliest event reported):&nbsp;&nbsp;12/19/2013 </b>
			</font>
		</div>


		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="5" Color="#000000">
				<b>Dynavax Technologies Corporation</b>
			</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="2" Color="#000000">
				<b>(Exact name of registrant as specified in its charter)</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="3" Color="#000000">
				<b>Commission File Number:&nbsp;&nbsp;001-34207</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<table Cellspacing="0" Cellpadding="0" Width="100%" Border="0">
				<tr>
					<td Valign="bottom" Width="59%" Align="center">
						<div Align="center">
							<font Face="times New Roman" Size="3" Color="#000000">
								<b>Delaware</b>
							</font>
						</div>
					</td>
					<td Valign="bottom" Width="3%">
						<font Face="times New Roman" Size="1">
							&nbsp;&nbsp;
						</font>
					</td>
					<td Valign="bottom" Width="59%" Align="center">
						<div Align="center">
							<font Face="times New Roman" Size="3" Color="#000000">
								<b>33-0728374</b>
							</font>
						</div>
					</td>
				</tr>
				<tr>
					<td Valign="top" Align="center" Width="59%">
						<div Style="margin-left:2%; Text-indent:-2%" Align="center">
							<font Face="times New Roman" Size="2" Color="#000000">
								<b>(State or other jurisdiction of</b>
							</font>
						</div>
					</td>
					<td Valign="bottom" Width="3%">
						<font Face="times New Roman" Size="1">
							&nbsp;&nbsp;
						</font>
					</td>
					<td Valign="bottom" Align="center" Width="59%">
						<div Align="center">
							<font Face="times New Roman" Size="2" Color="#000000">
								<b>(IRS Employer</b>
							</font>
						</div>
					</td>
				</tr>
				<tr>
					<td Valign="top" Align="center" Width="59%">
						<div Style="margin-left:2%; Text-indent:-2%" Align="center">
							<font Face="times New Roman" Size="2" Color="#000000">
								<b>incorporation)</b>
							</font>
						</div>
					</td>
					<td Valign="bottom" Width="3%">
						<font Face="times New Roman" Size="1">
							&nbsp;&nbsp;
						</font>
					</td>
					<td Valign="bottom" Align="center" Width="59%">
						<div Align="center">
							<font Face="times New Roman" Size="2" Color="#000000">
								<b>Identification No.)</b>
							</font>
						</div>
					</td>
				</tr>
			</table>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="3" Color="#000000">
				<b>2929 Seventh Street, Suite 100</div><div Align="center">Berkeley, CA 94710-2753</b>
			</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="2" Color="#000000">
				<b>(Address of principal executive offices, including zip code)</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="3" Color="#000000">
				<b>(510) 848-5100</b>
			</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="2" Color="#000000">
				<b>(Registrant&#146;s telephone number, including area code)</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="3" Color="#000000">
				<b> </b>
			</font>
		</div>
		<div Align="center">
			<font Face="times New Roman" Size="2" Color="#000000">
				<b>(Former name or former address, if changed since last report)</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>


	<div Align="left">
		<font Face="times New Roman" Size="2" Color="#000000">
			<b>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<BR><BR></b>
		</font>
	</div>


	<div Align="left">
		<font Face="times New Roman" Size="2" Color="#000000">
			<b>[&nbsp;&nbsp;]&nbsp;&nbsp;
			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
			[&nbsp;&nbsp;]&nbsp;&nbsp;
			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
			[&nbsp;&nbsp;]&nbsp;&nbsp;
			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
			[&nbsp;&nbsp;]&nbsp;&nbsp;
			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
			</b>
		</font>
	</div>


	<div>
		<font Size="1">&nbsp;</font>
	</div>
	<hr Size="4" Noshade Color="#000000" Align="left">
	<p Style='page-break-before:always'>
	<p Align="center">


		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div align="left">
			<font Face="times New Roman" Size="2" Color="#000000">
				<b>Item 8.01.&nbsp;&nbsp;&nbsp;&nbsp;Other Events</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div  align="left" Style="text-indent:4%">
			<font Face="times New Roman" Size="2" Color="#000000">
				On December 19, 2013, we issued a press release titled "Dynavax Announces Submission of Responses to EMA Day 120 List of Questions for HEPLISAV(TM) MAA." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>


		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div align="left">
			<font Face="times New Roman" Size="2" Color="#000000">
				<b>Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</b>
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>
		<div  align="left" Style="text-indent:4%">
			<font Face="times New Roman" Size="2" Color="#000000">
				(d) Exhibits. </div><div align="left" style="text-indent:4%">The following exhibit is furnished herewith: <p>EX-99.1 Press Release, dated December 19, 2013, titled "Dynavax Announces Submission of Responses to EMA Day 120 List of Questions for HEPLISAV(TM) MAA".
			</font>
		</div>
		<div>
			<font Size="1">&nbsp;</font>
		</div>


	<hr  Size="3" Color="#cceeff" Width="100%" Align="center">
	<p Align="center"><font Size="2">&nbsp;</font>
	<div Align="center">
		<font Face="times New Roman" Size="2" Color="#000000">
			<b>SIGNATURES</b>
		</font>
	</div>
	<div>
		<font Size="1">&nbsp;</font>
	</div>
	<div align="left" Style="text-indent:4%">
		<font Face="times New Roman" Size="2" Color="#000000">
			Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
			duly authorized.
		</font>
	</div>
	<div>
		<font Size="1">&nbsp;</font>
	</div>
	<div>
		<table Cellspacing="0" Cellpadding="0" Width="100%" Border="0">


			<tr>
				<td Valign="top" Colspan="3" Width="53%">
					&nbsp;
				</td>
				<td Valign="bottom" Width="3%">
					&nbsp;
				</td>
				<td>
					&nbsp;
				</td>
				<td Valign="bottom" Width="3%">
					&nbsp;
				</td>
				<td Valign="top" Align="center" Width="3%">
					&nbsp;
				</td>
				<td Valign="bottom" Width="3%">
					&nbsp;
				</td>
				<td Valign="top" Width="53%">
					<div Style="margin-left:2%; Text-indent:-2%">
						<font Face="times New Roman" Size="2" Color="#000000">
							Dynavax Technologies Corporation
						</font>
					</div>
				</td>
			</tr>
			<tr>
				<td>
					&nbsp;
				</td>
			</tr>
			<tr>
				<td>
					&nbsp;
				</td>
			</tr>
			<tr>
				<td Valign="top" Colspan="3" Width="53%">
					<div Style="margin-left:2%; Text-indent:-2%">
						<font Face="times New Roman" Size="2" Color="#000000">
							Date: December 19, 2013
						</font>
					</div>
				</td>
				<td Valign="bottom" Width="3%">
					&nbsp;
				</td>
				<td>
					&nbsp;
				</td>
				<td Valign="bottom" Width="3%">
					&nbsp;
				</td>
				<td Valign="top" Align="center" Width="3%">
					<div Align="center">
						<font Face="times New Roman" Size="2" Color="#000000">
							By:
						</font>
					</div>
				</td>
				<td Valign="bottom" Width="3%">
					&nbsp;
				</td>
			<td Valign="top" Width="53%">
				<div Style="margin-left:2%; Text-indent:-2%">
					<font Face="times New Roman" Size="2" Color="#000000">
						/s/&nbsp;&nbsp;&nbsp;&nbsp;Michael Ostrach</font>
				</div>
				<hr Noshade Align="left" Color="#000000">
			</td>
		</tr>
		<tr>
			<td>
				&nbsp;
			</td>
			<td Valign="bottom" Width="3%">
				&nbsp;
			</td>
			<td>
				&nbsp;
			</td>
			<td Valign="bottom" Width="3%">
				&nbsp;
			</td>
			<td>
				&nbsp;
			</td>
			<td Valign="bottom" Width="3%">
				&nbsp;
			</td>
			<td>
				&nbsp;
			</td>
			<td Valign="bottom" Width="3%">
				&nbsp;
			</td>
			<td Valign="bottom" Width="53%">
				<div Style="margin-left:2%; Text-indent:-2%">
					<font Face="times New Roman" Size="2" Color="#000000">
						Michael Ostrach</font>
				</div>
			</td>
		</tr>
		<tr>
			<td>
				&nbsp;
			</td>
			<td Valign="bottom" Width="3%">
				&nbsp;
			</td>
			<td>
				&nbsp;
			</td>
			<td Valign="bottom" Width="3%">
				&nbsp;
			</td>
			<td>
				&nbsp;
			</td>
			<td Valign="bottom" Width="3%">
				&nbsp;
			</td>
			<td>
				&nbsp;
			</td>
			<td Valign="bottom" Width="3%">
				&nbsp;
			</td>
			<td Valign="bottom" Width="53%">
				<div>
					<font Face="times New Roman" Size="2" Color="#000000">
						Vice President
					</font>
				</div>
			</td>
		</tr>
		<tr>
			<td>
				&nbsp;
			</td>
		</tr>
		<tr>
			<td>
				&nbsp;
			</td>
		</tr>


	</table>
</div>


		<p Style='page-break-before:always'>
		<hr  Size="3" Color="#cceeff" Width="100%" Align="center">
		<p Align="center"><font Size="2">&nbsp;</font>
		<div Align="center">
			<font Face="times New Roman" Size="2" Color="#000000">
			<b>EXHIBIT INDEX</b>
		</font>
		</div>
		<div>
			&nbsp;
		</div>
		<div Align="center">
			<table Cellspacing="0" Cellpadding="0" Width="100%" Border="0">
				<tr>
					<td Valign="top" Align="left">
						<div Align="left">
							<font Face="times New Roman" Size="2" Color="#000000">
								<b>Exhibit&nbsp;No.</b>
							</font>
						</div>
						<hr Size="2" Noshade Width="48" Color="#000000">
					</td>
					<td Valign="top" Width="3%" Align="left">
						<font Face="times New Roman" Size="2">&nbsp;&nbsp;</font>
					</td>
					<td Valign="top" Width="100%" Align="left">
						<div>
							<font Face="times New Roman" Size="2" Color="#000000">
								<b>Description</b></font>
						</div>
						<hr Size="2" Noshade Width="73" Align="left" Color="#000000">
					</td>
				</tr>


				<tr>
					<td Valign="top" Align="left">
						<div Align="top">
							<font Face="times New Roman" Size="1" Color="#000000">
								EX-99.1
							</font>
						</div>
					</td>
					<td Valign="top" Width="3%" Align="left">
						<font Face="times New Roman" Size="2">&nbsp;&nbsp;</font>
					</td>
					<td Valign="top" Width="100%" Align="left">
						<div>
							<font Face="times New Roman" Size="2" Color="#000000">
								Press Release, dated December 19, 2013, titled </font>
						</div>
					</td>
				</tr>


		</table>
			</div>


	</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>rrd398069_40304.htm
<DESCRIPTION>PRESS RELEASE, DATED DECEMBER 19, 2013, TITLED
<TEXT>
<HTML>
<HEAD>
<TITLE>Dynavax Technologies</TITLE>
</HEAD>
<BODY LINK="#0000ff">
<B><FONT SIZE=4 COLOR="#008080"><FONT SIZE=4 COLOR="#008080"><P>Dynavax Technologies</P>
<P>2929 Seventh Street, Suite 100  </P>
<P>Berkeley, CA 94710</P>
</FONT></FONT><FONT FACE="Arial"></B></FONT>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=579 DIR="LTR">
<TR><TD WIDTH="50%" VALIGN="TOP">
<B><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3><P>Contact:</B></FONT></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="47%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3><P>Michael Ostrach</FONT></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="47%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP" HEIGHT=28>
<FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3><P>Vice President and Chief Business Officer </FONT></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP" HEIGHT=28><P></P></TD>
<TD WIDTH="47%" VALIGN="TOP" HEIGHT=28><P></P></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP" HEIGHT=9>
<FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3><P>510-665-7257</FONT></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP" HEIGHT=9><P></P></TD>
<TD WIDTH="47%" VALIGN="TOP" HEIGHT=9><P></P></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP" HEIGHT=9>
<FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3><P>mostrach@dynavax.com</FONT></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP" HEIGHT=9><P></P></TD>
<TD WIDTH="47%" VALIGN="TOP" HEIGHT=9><P></P></TD>
</TR>
</TABLE>
</CENTER></P>
<B><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3><P ALIGN="CENTER"></P>
</FONT></FONT><FONT FACE="Arial" SIZE=4><FONT FACE="Arial" SIZE=4><P ALIGN="CENTER">Dynavax Announces Submission of Responses to EMA Day 120 List of Questions for HEPLISAV&trade; MAA</P>
</FONT></FONT><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3><P ALIGN="CENTER"></P>
</B><P>BERKELEY, CA&nbsp;-- (Marketwired) --&nbsp;12/19/13&nbsp;--&nbsp;Dynavax Technologies Corporation (NASDAQ:&nbsp;DVAX)&nbsp;confirmed today that during the fourth quarter of 2013 it had submitted its responses to the&nbsp;Day 120 List of Questions issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding Dynavax's Marketing Authorization Application (MAA) for its HEPLISAV investigational adult hepatitis B vaccine.</P>
<P>Dynavax expects to receive the EMA Day 180 List of Outstanding Issues during the first quarter of 2014.&nbsp; </P>
<B><EM><P>About HEPLISAV</P>
</B></EM><P>HEPLISAV is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.</FONT></FONT><FONT SIZE=3>&nbsp;</FONT><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3>Dynavax</FONT></FONT><FONT SIZE=3>&nbsp;</FONT><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3>has worldwide commercial rights to HEPLISAV.</P>
<B><EM><P>About</FONT></FONT></EM><I><FONT SIZE=3>&nbsp;</I></FONT><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3><EM>Dynavax</P>
</B></EM><P>Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. </FONT></FONT><FONT SIZE=3>&nbsp;</FONT><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3>Dynavax's</FONT></FONT><FONT SIZE=3>&nbsp;</FONT><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3>lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit</FONT></FONT><FONT SIZE=3>&nbsp;</FONT><FONT FACE="Arial" SIZE=3><FONT FACE="Arial" SIZE=3>www.dynavax.com.</P>
</FONT></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
